Cigna, Express Scripts To Face Tough Antitrust Review
Cigna's $67 billion purchase of Express Scripts is set to face rigorous antitrust scrutiny amid a wave of deals integrating insurers and pharmacy benefits managers — especially given the government's recent...To view the full article, register now.
Already a subscriber? Click here to view full article